Format

Send to

Choose Destination
J Am Geriatr Soc. 2018 Oct;66(10):1948-1955. doi: 10.1111/jgs.15508. Epub 2018 Sep 17.

Cumulative Antidepressant Use and Risk of Dementia in a Prospective Cohort Study.

Author information

1
Institute for Public Health Genetics, University of Washington, Seattle, Washington.
2
Institute for Systems Biology, Seattle, Washington.
3
School of Pharmacy, University of Washington, Seattle, Washington.
4
Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
5
Department of Pharmaceutics, University of Washington, Seattle, Washington.
6
Department of Epidemiology, School of Medicine, University of California, Irvine, California.
7
Department of Bioethics and Humanities, University of Washington, Seattle, Washington.
8
Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington.

Abstract

OBJECTIVES:

To determine whether antidepressant use is associated with dementia risk.

DESIGN:

Prospective cohort study.

SETTING:

Kaiser Permanente Washington (KPWA), an integrated healthcare delivery system.

PARTICIPANTS:

Community-dwelling individuals aged 65 and older without dementia and with 10 years or more of KPWA enrollment at baseline (N=3,059).

MEASUREMENTS:

Primary exposures were selective serotonin reuptake inhibitors (paroxetine vs other), tricyclic antidepressants, and serotonin antagonist and reuptake inhibitors. Using health plan pharmacy data, we calculated cumulative medication exposure, defined as total standardized daily doses (TSDDs), over rolling 10-year windows. Exposure in the most recent year was excluded to avoid use related to prodromal symptoms. The Cognitive Abilities Screening Instrument was administered every 2 years; low scores triggered clinical evaluation and consensus diagnosis procedures. Dementia risk was estimated according to medication use using Cox proportional hazards models.

RESULTS:

During a mean follow-up of 7.7 years, 775 participants (25%) developed dementia; 659 (22%) developed possible or probable Alzheimer's disease. Individual antidepressant classes were not associated with differences in dementia risk, although paroxetine use was associated with higher risk of dementia for all TSDD categories than no use (0-90 TSDDs: hazard ratio (HR)=1.69, 95% confidence interval (CI)=1.18-2.42; 91-365 TSDDs: HR=1.40, 95% CI=0.88-2.23; 366-1095 TSDDs: HR=2.13, 95% CI=1.32-3.43; ≥1095 TSDDs: HR=1.42, 95% CI=0.82-2.46).

CONCLUSION:

Most commonly prescribed nonanticholinergic depression medications used in late life do not appear to be associated with dementia risk. Paroxetine and other anticholinergic antidepressants may be exceptions in older individuals. Future studies are warranted to improve scientific understanding of potential associations in other settings and populations.

KEYWORDS:

antidepressants; dementia; depression

PMID:
30221747
DOI:
10.1111/jgs.15508

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center